- AbbVie to enter deal with HotSpot for up to $335m
- EMA accepts marketing authorisation application for ALS treatment, tofersen
- Positive results for BioVie’s Parkinson’s and Alzheimer’s phase 2 trials
- Nkarta data supports natural killer cells in cancer treatment
- Aptamer Group sign deals to develop Optimer solutions
- Innovent Biologics and UNION Therapeutics announce first dosing of Chinese subject in phase 1 study
- Amgen’s obesity drug appears promising with few side effects
- New insights into HIV vaccine revealed by researchers
- Scottish Medicines Consortium approves Bayer’s Kerendia for NHS Scotland
- GSK’s two new cancer drugs look promising
- AstraZeneca and Merck launch prostate cancer awareness campaign
- AstraZeneca and MSD launch prostate cancer awareness campaign
- FDA grants approval to WISE for neuromonitoring cortical strip
- Eli Lilly’s COVID-19 drug bebtelovimab loses FDA authorisation
- Pulmonx secure Japanese approval for Zephyr Valve for COPD/emphysema